Scarica l'app Stockscreener
1.0893
3.47%
-0.0307
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.12
Aprire:
$1.1
Volume 24 ore:
800.25K
Relative Volume:
0.15
Capitalizzazione di mercato:
$318.31M
Reddito:
-
Utile/perdita netta:
$-63.08M
Rapporto P/E:
-4.0344
EPS:
-0.27
Flusso di cassa netto:
$-72.53M
1 W Prestazione:
+5.99%
1M Prestazione:
+3.95%
6M Prestazione:
+38.60%
1 anno Prestazione:
-33.67%
Intervallo 1D:
$1.07
$1.12
Intervallo di 1 settimana:
$0.99
$1.18
Portata 52W:
$0.515
$1.66
Ocugen Inc Stock (OCGN) Company Profile
Nome
Ocugen Inc
Settore
Industria
Telefono
484-328-4701
Indirizzo
11 GREAT VALLEY PARKWAY, MALVERN, PA
Confronta OCGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.09 | 341.68M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.58 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.35 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.17 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
593.70 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
292.62 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-15 | Iniziato | Maxim Group | Buy |
| 2023-03-01 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Iniziato | Mizuho | Buy |
| 2022-06-15 | Ripresa | ROTH Capital | Buy |
| 2022-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Iniziato | Noble Capital Markets | Outperform |
| 2021-06-11 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
Mostra tutto
Ocugen Inc Borsa (OCGN) Ultime notizie
Ocugen Inc. Stock Analysis and ForecastFree Risk Assessment Services - PrintWeekIndia
What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com
What drives Ocugen Inc. stock priceStrongest growth potential - Autocar Professional
When is the best time to buy Ocugen Inc. stockMarket-leading growth rates - jammulinksnews.com
First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
Ocugen, Inc. Announces New Appointments to its Retina Scientific Advisory Board and Executive Leadership Team - VisionMonday.com
Is Ocugen Inc. a good long term investmentRobust investment performance - jammulinksnews.com
What analysts say about Ocugen Inc. stockHigh-velocity capital appreciation - jammulinksnews.com
Ocugen announces appointments to retina scientific advisory board and executive leadership team - Ophthalmology Times
Ocugen Bets Big On Gene Therapy Despite Major Setbacks - Finimize
Ocugen, Inc. Announces New Appointments to Retina Scientific Adv - GuruFocus
Ocugen expands advisory board and leadership team for gene therapy push - Investing.com India
Ocugen, Inc. Strengthens Retina Scientific Advisory Board and Leadership Team to Advance Gene Therapy Development for Blindness Diseases - Quiver Quantitative
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team - GlobeNewswire
Ocugen Assembles Elite Gene Therapy Team: 3 Top Retina Experts Join as Company Targets Triple BLA Filing - Stock Titan
Ocugen doses first subject in trial of modifier gene therapy candidate - Yahoo Finance
Ocugen Doses First Patient in Pivotal Trial for Stargardt Gene Therapy - MyChesCo
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
Ocugen’s Phase 1 Study on OCU200: A Potential Game-Changer for Diabetic Macular Edema - TipRanks
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 - GuruFocus
Ocugen doses first patient in phase 2/3 Stargardt disease trial - Investing.com Australia
Ocugen doses first patient in phase 2/3 Stargardt disease trial By Investing.com - Investing.com South Africa
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 - GlobeNewswire
Revolutionary Gene Therapy Shows 48% Disease Slowdown in Stargardt Blindness Trial - Stock Titan
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results - Ocugen
Ocugen to Host Conference Call on Friday, August 1 at 8:30 - GlobeNewswire
Ocugen Inc Azioni (OCGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.74%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):